PT-141 + oxytocin nasal spray
Ten milligrams of the melanocortin agonist and five of the nonapeptide hormone in one metered spray, the behavioural-research combination, honestly framed as a convenience rather than a synergy claim.
- ISO-certified laboratory
- COA per batch, ≥99% HPLC
- Not yet available, in development
- Research use only
Two mechanisms, one pump
PT-141 (bremelanotide) works melanocortin receptors centrally, the arousal-signal side, not the blood-flow side its better-known comparators occupy. Oxytocin runs an entirely separate receptor system with its own contested intranasal literature. The combination serves protocols studying both; no synergy is claimed because none is demonstrated. The PT-141 compound page and the oxytocin page keep the two research records apart.
Both molecules clear the spray shelf’s chain-length bar, nine residues and a cyclic heptapeptide core, making mucosal delivery chemically credible in a way most of the catalogue cannot match.
| Compounds | PT-141 10 mg + oxytocin 5 mg |
| Format | Metered nasal spray |
| PT-141 target | Central melanocortin receptors |
| Oxytocin target | Oxytocin receptor system |
| Purity | ≥ 99% (HPLC), both |
| Combination status | Convenience, not proven synergy |
| Category | Research use only |
The COA reports both analytes separately against the one lot, two identities, one document.
Before the PT-141 + oxytocin nasal spray reaches the bench
Standard spray regimen; the combination changes storage not at all.
Two molecules, one mucosa
Why a melanocortin agonist and a hormone share a single pump, and what nasal delivery asks of each.
Both compounds here clear the chain-length bar the spray shelf sets: oxytocin is a nine-residue hormone, PT-141 a cyclic heptapeptide core, and short sequences are the only ones for which mucosal crossing stays chemically credible. That shared brevity is why the pairing lives in a bottle at all. Nasal delivery also drops oxytocin into the route its own contested literature keeps arguing over, whether the hormone reaches the brain this way remains genuinely unsettled across the intranasal oxytocin literature on PubMed, and the page says so.
Framed honestly, a pt-141 oxytocin spray is a convenience, not a synergy, two separate receptor systems addressed through one pump because a protocol studying both would otherwise juggle two devices. PT-141 works the central melanocortin receptors, the arousal-signal side its vascular comparators never occupy; oxytocin runs its own receptor system entirely. Ten milligrams of the first and five of the second share the bottle, and the certificate reports each identity on its own against the single lot.
Prime, chill, and record
One bottle, two analytes, and a discipline that keeps both traceable to the same certificate.
The mechanics are the standard spray regimen, and carrying two compounds changes none of them: prime the fresh pump until the stem clears air, keep the bottle upright so the dip tube stays sealed, and refrigerate between sessions. What the combination does change is the paperwork you log against, a dual-analyte certificate, the melanocortin agonist and the hormone each measured on the one lot, read the way the certificate page describes. Note both purities beside the batch number so a single record carries the whole bottle.
Date the bottle at first actuation and read the opened-pump window in weeks, not off the calendar. Because two molecules age inside one carrier, an undated combination bottle is doubly hard to defend later: you cannot say which analyte, if either, still sits near its certified purity. Pair each session’s actuation count with the lot, keep the priming losses in a separate waste tally, and the record stays honest about what one pump actually delivered.
The behavioural shelf
The upstream axis regulator, and the melanocortin parent compound.
The science behind PT-141 + oxytocin
Both compounds and the shelf they define.
Questions about the PT-141 + oxytocin nasal spray
Combination-spray clarity.